WCM
APLS

Weld Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Weld Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,230
Closed -$242K – 313
2020
Q4 		$242K Sell
4,230
-7,130
-63% -$302K 0.1% 339
2020
Q3 		$343K Buy
+11,360
New +$339K 0.14% 258
2019
Q3 		– Sell
-17,321
Closed -$439K – 756
2019
Q2 		$439K Buy
+17,321
New +$352K 0.08% 425

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Weld Capital Management's APLS Position: Q1 2021 in Review

Weld Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2021, closing a stake of 4,230 shares — an estimated $242K sold.

Weld Capital Management first reported a position in APLS in Q2 2019 and held it in 3 quarters. The position peaked at $439K in Q2 2019. 175 funds tracked by Wall St. Rank hold APLS as of Q1 2021.

  • Weld Capital Management reported no remaining Apellis Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Weld Capital Management sold 4,230 Apellis Pharmaceuticals shares in Q1 2021, an estimated $242K.
  • Weld Capital Management first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 3 quarters.
  • Weld Capital Management's Apellis Pharmaceuticals position peaked at $439K in Q2 2019.
  • 175 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2021.

Based on Weld Capital Management's 13F filing for Q1 2021, filed 17 May 2021.